BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AEterna Zentaris (AEZS) to Present Proof of Concept for Disorazol Z Cytotoxic Conjugates Such as AEZS-125 in Ovarian Cancer Mouse Model at Upcoming ENA Symposium


11/1/2012 10:16:47 AM

QUÉBEC CITY, Nov. 1, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its Director of Preclinical Development, Babette Aicher, PhD, will be making a poster presentation on preclinical results for disorazol Z cytotoxic conjugates, such as AEZS-125, in ovarian cancer, at the upcoming 24th EORTC-NCI-AACR (ENA) Symposium on "Molecular Targets and Cancer Therapeutics", which will be held November 6-9, 2012 in Dublin, Ireland. The study is funded through a grant from the German Ministry of Education and Research.

Abstract #330: "Highly Potent Cytotoxic Conjugates of Disorazol Z Linked to a LHRH-Receptor Targeting Peptide, such as AEZS-125, Interfere with Cell Cycle Progression in Human Cancer Cell Lines and Suppress Tumor Growth in a LHRH Receptor Positive Ovarian Cancer Xenograft Model ", B. Aicher, T. Schuster, L. Blumenstein, P. Schmidt, H. Irschik, R. Jansen, R. Mueller, E. Guenther, M. Teifel.
Session: Monoclonal Antibodies and Targeted Toxins/Nuclides
Poster Board: 080
Date& Time: Thursday, November 8, 2012, from 12 noon to 2:15 pm (local time)
Venue: Convention Centre Dublin

About Disorazol Z cytotoxic conjugate, AEZS-125

AEZS-125 is a disorazol Z (AEZS-137) cytotoxic conjugate linked to a Luteinizing Hormone-Releasing Hormone (LHRH)-receptor targeting peptide. Disorazol Z is a novel natural compound isolated from myxobacterium Soranglium cellulosum with outstanding cytotoxic activity. Disorazol Z is a macrocyclic polyketide which is available via fermentation in high yield and purity. Besides tubulin binding, disorazol Z has pro-apoptotic properties and arrested cancer cells in G2 stage of the cell cycle at subnanomolar concentrations. Disorazol Z is an ideal partner for the formation of cytotoxic conjugates with peptides and proteins to selectively target cancer cells.

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. For more information please visit www.aezsinc.com.

SOURCE AETERNA ZENTARIS INC.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES